gubra obesity - Search News

AbbVie, obesity

AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Crain's Chicago Business · 2d

AbbVie enters obesity drug market with Danish drugmaker

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.

MarketWatch · 2d

AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.

Seeking Alpha · 1d

AbbVie Steps Into The Ring In The Obesity Drug Wars

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.

Investor's Business Daily on MSN · 1d

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

21hon MSN

Healthy Returns: AbbVie is the newest potential weight loss drug market player

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

FierceBiotech2d

AbbVie pays Gubra $350M to make late play for obesity space

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

How the race for the next obesity drug is shaping up

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

BioPharma Dive2d

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie pays Gubra $350m upfront to enter obesity field

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

The Pharma Letter2d

Obesity late-comer AbbVie teams up with Gubra

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results